en · de · es · pt
thymosin-alpha-1-notes.peptides6155.com › Wiki › Molecular Background And Immune Action — Common Mistakes

Molecular Background And Immune Action — Common Mistakes

By Editorial Desk · published 2026-02-28 · last reviewed 2026-04-20 · Wiki

细胞因子 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-04-20. Where a claim depends on a specific study, the study is described rather than over-claimed.

Molecular Background and Immune Action

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

免疫调节机制与信号

临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善,但临床终点获益在不同研究中并不一致。系统综述指出,研究间在人群、剂量和联合方案上差异较大,难以汇总结论。因此,Tα1的确切临床地位仍属开放问题,需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。

胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明,它可促进未成熟T细胞向成熟T细胞分化,并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子,从而更有效地呈递抗原。此外,自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体,而是调节宿主免疫应答的强度与方向。

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular mass≈3,108 DaSynthetic 28-residue peptide
Amino acid count28N-terminal serine carries an acetyl group
AppearanceWhite to off-white powderLyophilized solid
Water solubilityFreely solubleDissolves in aqueous buffer
Common synonymsThymalfasin; Tα1Thymalfasin is the international nonproprietary name

Research History and Clinical Assessment

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.

Related pages on this site

Stability, Storage, and Analysis

Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.

Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.

Background from the literature

All of these instruments provide a high mass accuracy (<2–3 ppm with external calibrant and <1–2 ppm with internal), a high resolving power (up to 240,000 at m/z 400), a high dynamic range and high sensitivity.

Directed by Sheila Hayman, made by Uden Associates 8 November Rebuilding Berlin, how German telecommunication and electrical engineers found great difficulty in connecting the infrastructure and technology of East and West Berlin, which were largely totally incompatible, and why the two technological systems were so different; East and West Germany were founded in 1953; the trains in East (Deutsche Reichsbahn or DR) and West Germany ran on electric motors that worked in opposite ways; Erich Kratky of Berliner Verkehrsbetriebe (former West Berlin Public Transport) and how East Berlin drivers had 60% of those in West Berlin; Mahlow station, on the S2 line on the Berlin S-Bahn, was completely rebuilt in 1991, opening on 31 August 1992; before 1989, West Berlin could not connect to any neighbouring electrical power networks, so had to make all of its own power itself, by nine power stations; in 1992 West Berlin could not make enough electrical power;Jürgen Beyer of the East Berlin Electricity Board; in 1992 East and West Germany could not connect their electricity systems together; Klaus Krämer of the West Berlin Electricity Board, and how East German load frequency control (LFC) was not good enough for West Germany; East German power stations were polluting; Müggelsee in East Berlin; East Berlin had natural gas - from Russia - but West Berlin did not have natural gas, and had to produce its own gas from processing, and there were many more gas leaks in East Berlin, run by the Berlin Gas Board, and British Gas plc was installing most of the new plastic gas mains in East Berlin; one fifth of housing in East Berlin was uninhabitable, due to lack of renovation and unsafe electrical wiring; much housing in East Berlin did not have any bathrooms; the post system in East Berlin was three times slower than West Berlin, as it was all sorted by hand, and mail hand to be sent in standard envelopes only, in East Germany - the two post systems were incompatible, and East and West Germany had totally different postcode systems, although both had four digits, so a letter was put in front of each Deutsche Post postcode, to show if it was an East or West German postcode; in 1952, telephone connections between East and West Germany were stopped, but four lines were installed in 1972; the East German telephone exchanges were all mechanical, and could not transmit any digital communications; one in ten people in East Berlin had a phone - telecommunications in East Berlin were hopeless and expensive; in 1992 Deutsche Telekom connected East and West Berlin, and the price would be a local call, not the price of an international call, under the phrase Wir schaffen Verbingdungen; not only were East German telecommunications often impossible, but the Stasi secret police were listening in to most calls; Rudolf Reichel of the former East German Economic Institute; science research in East Germany had been greatly restricted; Volker Hassemer; East Germans viewed West Germans as selfish, and West Germans viewed East Germans as backward. Narrated by Su-Lin Looi, directed by Cosima Dannoritzer, produced by Karl Sabbagh, made by Skyscraper Productions 15 November 21st Century Jet, how the Boeing 777 moved from the drawing board to manufacture in 1992, with the innovative new method called CATIA; the Boeing 777 was the largest jet aircraft to have been developed mostly by computer, with assembly beginning in January 1993; there were 10,000 people in the 777 programme, who met the managers in a weekly meeting; meeting the needs of Robert Crandall of American Airlines, and competition from the new Airbus A340; parts of the tail were built in Australia; the nose cone and flaps were made in Italy; the landing gear was made in Canada, the US, and France; parts of the wing ribs and passenger doors were made in Japan; the nose landing gear door was made in Belfast; some of the electronics was made in England; there were about 230 design teams, from different manufacturers; the CATIA system was a digital mockup; Thomas Gaffney, head of passenger doors; Henry Shomber, one of the chief engineers; John Roundhill, a chief project engineer; United Airlines placed the first order, which started the project; Al Tyler of Aerospace Technologies of Australia (ASTA), who made the 777 rudder - the company became Boeing Australia; John King, Baron King of Wartnaby of British Airways visits to look at legroom for the new 777. Narrated by Simon Prebble, directed by Karl Sabbagh, made by Skyscraper Productions 22 November The Puzzle of HIV, scientists after ten years did not understand how HIV worked; immunologists Anthony Fauci and Max Essex; Angus Dalgleish of St George's, University of London; virologist Stephen S. Morse, and the origination of viruses, and how most pandemics originated in China; Stella Knight of the MRC, and dendritic cells, researched by Brigid Balfour; French immunologist Jean-Claude Ameisen of the Pasteur Institute of Lille; virologist Jonas Salk; Claude Nicolau, and the CD4 glycoprotein. Narrated by Scottish actress Sandra Clark, directed by Nigel Maslin, produced by Chris Haws, made by InCA Productions 29 November The Alpha Link, much of medical understanding of radiation protection and health comes from what occurred in Japan in August 1945. Martin Gardner (1940–93), an epidemiologist, and Professor of Medical Statistics at the University of Southampton, thought that health was affected by working in a nuclear power station, which the British nuclear industry vehemently would not believe. Directed by Vivienne King, made by Box Productions 6 December Toying with the Future, about electronic children's toys, visiting Ocean Software in Manchester; Brian Sutton-Smith of the University of Pennsylvania, and how toys were small replicas of large world events; Eugene F. Provenzo of the University of Miami and how the culture of childhood began in the early 1700s, and how German Friedrich Fröbel developed educational toys in the early 1800s, but it often lacked fun; Meccano Ltd sets, developed by Frank Hornby, launching the international Meccano Guild network of children's mechanical clubs in 1919, publicised by the Meccano Magazine; Richard Gregory, neuropsychologist at the University of Bristol, and his Exploratory Hands-on Science Centre, which closed in 1999, replaced by We the Curious in 2000; toy designer Patrick Rylands; Gary Bracey of Ocean Software; Keith Tinman, computer game musician; Elizabeth Curran of GameTek; Ocean Software designers Ray Coffey, James Higgins and Dawn Drake. Directed by Christopher Rawlence, produced by Debra Hauer, made by Rawlence Hauer Productions 13 December The Elements, a repeat of the 20 October 1991 episode 20 December E.T. Please Phone Earth, about the SETI Institute, with Prof Philip Morrison, a professor of physics at MIT, who played a starring if not dangerous role in the Manhattan Project; Jill Tarter at the Hat Creek Radio Observatory in California; Dr John Billingham, a British medical doctor at the Ames Research Center in California; Prof Antony Hewish of the University of Cambridge, who discovered pulsars in 1967; Frank Drake, and his work at the National Radio Astronomy Observatory in Green Bank, West Virginia; Barney Oliver of SETI; David Blair of the University of Western Australia; Paul Horowitz of Harvard University; the Ohio State University Radio Observatory (known as Big Ear) and its 1977 Wow! signal; Jack Cohen; chemist Stanley Miller and his 1953 experiment; blind SETI investigator Kent Cullers; and biologist Jared Diamond from UCLA. Jointly made with ABC of Australia, narrated by Heather Couper, directed by Richard Smith, produced by Stuart Carter, made by Pioneer Productions

== Legacy == Ajayaghosh's research have been principally in the fields of supramolecular chemistry, chemosensors, low band-gap polymers, fluorescent gels, organic nanostructures, and photoresponsive systems and he is reported to have done extensive researches on supramolecular architecture and light-induced sensor systems. He is known to have pioneered the study of molecular self-assembly in India and is credited with the creation of a new category of self-assembled materials that are functionally soft. His work assisted in the design of larger molecular structures using self-assembling molecules and demonstrated ways to control their electrical conductivity through controlling external factors like temperature which have reported use in applications involving light harvesting, sensing, imaging, and security. He was the first scientist to design functional Phenylenevinylene-based Organogels from designed building blocks, which has been detailed in his article, First Phenylenevinylene Based Organogels: Self-Assembled Nanostructures via Cooperative Hydrogen Bonding and π-Stacking, published in 2001. One of the commercial applications of his research is secret writing, thermally writable, non-copyable, and erasable fluorescent images useful for secret documentation by using a fluorescent gelator entrapped in a polystyrene film and the process has been developed by his team. His studies have been documented in several peer-reviewed articles; ResearchGate and Google Scholar, online repositories of scientific articles, have listed 202 and 162 of them respectively.

== Veterinary use == Buprenorphine is commonly used as a long-lasting post-operative analgesic in small animal veterinary practice. Buprenorphine can be administered via subcutaneous, transdermal, intravenous, or intramuscular routes. Buprenorphine provides analgesia for 6–8 hours in dogs and 4–8 hours in cats when administered as an intramuscular or intravenous injection. Buprenorphine as a partial agonist of the mu-receptor has less adverse effects than full agonists. A transdermal application can provide analgesia for up to 4 days in cats. The oral-transmucosal route has been investigated due to the potential for client administration but variability in bio-availability and other issues limit this usage. When used in combination with local anaesthetics or a non-steroidal anti-inflammatory drug buprenorphine provides good analgesia for ovariohysterectomies and orchidectomies. In horses buprenorphine can be used for castration and dental extraction; however, buprenorphine is not commonly used in horses as a post-operative analgesic due to potential for adverse gastrointestinal effects and locomotive stimulation. Buprenorphine is commonly given alongside acepromazine or a2 adrenergic receptor agonists

Testosterone can be administered by intramuscular injection either as an aqueous suspension of testosterone or as an oil solution or aqueous suspension of testosterone esters such as testosterone propionate, testosterone enanthate, testosterone cypionate, testosterone undecanoate, and testosterone isobutyrate. An even longer-acting testosterone ester that was developed but ultimately never marketed is testosterone buciclate. These preparations are prodrugs of progesterone that have a long-lasting depot effect when injected into muscle or fat, ranging from days to months in duration. The bioavailability of drugs that are administered intramuscularly is generally almost 95%. As oil solutions by intramuscular injection, the elimination half-lives of testosterone esters are 0.8 days for testosterone propionate, 4.5 days for testosterone enanthate, 20.9 days (in tea seed oil) and 33.9 days (in caster oil) for testosterone undecanoate, and 29.5 days for testosterone buciclate. The pharmacokinetics of testosterone cypionate are said to be the same as those of testosterone enanthate, with "extremely comparable" patterns of testosterone release. Due to their varying and different elimination half-lives, the different intramuscular testosterone esters are administered with differing frequencies. Testosterone propionate is injected two to three times per week, testosterone enanthate and testosterone cypionate are injected once every two to four weeks, and testosterone undecanoate and testosterone buciclate are injected once every 10 to 14 weeks.

Sources: en.wikipedia.org

Reference notes

==== Consensus paper ==== In 2013 the E.S.PKU delegates launched a paper describing the needs for a better and equal treatment across Europe. This paper subsequently lead to the first European Guidelines for Phenylketonuria.

For a soleus receptor, Houk and Simon obtain average values of K=57 pulses/sec/kg, A=0.31, a=0.22 sec−1, B=0.4, b=2.17 sec−1, C=2.5, c=36 sec−1 . When modeling a cat stretch reflex, Lin and Crago improved upon this model by adding a logarithmic nonlinearity before the Houk and Simon model and a threshold nonlinearity after.

=== Zeolitic imidazolate frameworks (ZIFs) === Several different mechanical phenomena have been observed in zeolitic imidazolate frameworks (ZIFs), the most widely studied MOF for mechanical properties due to their many similarities to zeolites. General trends for the ZIF family are the tendency of the Young's modulus and hardness of the ZIFs to decrease as the accessible pore volume increases. The bulk moduli of ZIF-62 series increase with the increasing of benzoimidazolate (bim−) concentration. ZIF-62 shows a continuous phase transition from open pore (op) to close pore (cp) phase when bim− concentration is over 0.35 per formular unit. The accessible pore size and volume of ZIF-62-bim0.35 can be precisely tuned by applying adequate pressures. Another study has shown that under hydrostatic loading in solvent the ZIF-8 material expands as opposed to contracting. This is a result of hyperfilling of the internal pores with solvent. A computational study demonstrated that ZIF-4 and ZIF-8 materials undergo a shear softening mechanism with amorphizing (at ~ 0.34 GPa) of the material under hydrostatic loading, while still possessing a bulk modulus on the order of 6.5 GPa. Additionally, the ZIF-4 and ZIF-8 MOFs are subject to many pressure dependent phase transitions.

Aspartic acid (symbol Asp or D; known as aspartate in its anionic form), is an α-amino acid that is used in the biosynthesis of proteins. The L-isomer of aspartic acid is one of the 22 proteinogenic amino acids, i.e., the building blocks of proteins. D-aspartic acid is one of two D-amino acids commonly found in mammals. Apart from a few rare exceptions, D-aspartic acid is not used for protein synthesis but is incorporated into some peptides and plays a role as a neurotransmitter/neuromodulator. Like all other amino acids, aspartic acid contains an amino group and a carboxylic acid. Its α-amino group is in the protonated –NH+3 form under physiological conditions, while its α-carboxylic acid group is deprotonated −COO− under physiological conditions. Aspartic acid has an acidic side chain (CH2COOH) which reacts with other amino acids, enzymes and proteins in the body. Under physiological conditions (pH 7.4) in proteins the side chain usually occurs as the negatively charged aspartate form, −COO−. It is a non-essential amino acid in humans, meaning the body can synthesize it as needed. It is encoded by the codons GAU and GAC. In proteins aspartate sidechains are often hydrogen bonded to form asx turns or asx motifs, which frequently occur at the N-termini of alpha helices. Aspartic acid, like glutamic acid, is classified as an acidic amino acid, with a pKa of 3.9; however, in a peptide this is highly dependent on the local environment, and could be as high as 14. The one-letter code D for aspartate was assigned arbitrarily, with the proposed mnemonic asparDic acid.

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha 1 made of?

It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.

Is thymosin alpha 1 a hormone?

It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.

Where is thymosin alpha 1 approved?

Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.

胸腺素α1如何影响T细胞?

它促进未成熟T细胞分化并增强成熟T细胞的增殖与细胞因子分泌。这些作用有助于放大抗原特异性免疫应答。

Network